PO-101 Management of direct oral anticoagulant (DOAC)-related bleeding with andexanet alpha or idarucizumab versus prothrombin complex concentrate (PCC) in patients with cancer: the MD Anderson experience
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI